Karyopharm Therapeutics Inc.
Karyopharm is a clinical-stage biopharmaceutical company developing selective inhibitor of nuclear export (SINE) compounds with minimal direct government dependence but subject to standard FDA drug-approval regulation.
BusinessWhat KPTI does
Karyopharm Therapeutics develops proprietary SINE compounds targeting nuclear export for oncology, hematology, and other indications. Revenue is primarily from research collaborations and potential future product sales; the company is pre-commercial or early-commercial stage with significant R&D burn.
12 months past · 3 months futureKPTI activity timeline
Lifetime Government AwardsKPTI federal contracts by year
Smart Money · 13F HoldingsHedge funds holding KPTI
Politicians Trading KPTIMembers of Congress with recent KPTI positions
Congressional TradesWho in Congress is trading KPTI
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills to WatchLegislation flagged by our analysis
Political ProfileWhere KPTI sits in Washington
Karyopharm has no active lobbying, minimal campaign engagement, and no named legislative winners/losers. Stock movement is driven by clinical trial results and FDA decisions, not political events.
Regulatory ExposureThreats & opportunities
Regulatory threats
- FDA clinical trial delays
- drug pricing pressure
Regulatory opportunities
- Orphan drug designation
- accelerated approval pathways
Live signals + predictions for KPTI — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades KPTI
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord